Form 4: Versant Venture Capital VI, L.P. Sells Shares of Monte Rosa Therapeutics, Inc. (GLUE)

Versant Venture Capital VI, L.P. reports the sale of Monte Rosa Therapeutics, Inc. shares over three days in September 2024.

Summary

• Versant Venture Capital VI, L.P., along with related entities, reported the sale of Monte Rosa Therapeutics, Inc. (GLUE) common stock.
• The sales occurred over three days: September 11, 2024, September 12, 2024, and September 13, 2024.
• On September 11, 2024, 541,897 shares were sold at a weighted average price of $6 per share.
• On September 12, 2024, 16,047 shares were sold at a weighted average price of $6.0017 per share.
• On September 13, 2024, 9,269 shares were sold at a weighted average price of $6.1603 per share.
• Following these transactions, Versant Venture Capital VI, L.P. directly owns 6,231,902 shares.
• Versant Vantage I, L.P. indirectly owns 2,097,938 shares.
• The reporting entities disclaim beneficial ownership of the indirectly held shares except to the extent of their pecuniary interests.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a report of stock sales, which doesn't inherently indicate positive or negative sentiment about the company's future. The impact depends on the reasons behind the sales, which are not disclosed.

Industry Context

This Form 4 filing indicates a significant shareholder, Versant Venture Capital, is reducing its position in Monte Rosa Therapeutics. This could be due to a variety of factors, including portfolio rebalancing, profit-taking, or a change in investment outlook. Monitoring subsequent filings and company announcements will be important to understand the full context.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and large shareholders.
• The reported transactions are relatively small compared to the total outstanding shares of Monte Rosa Therapeutics, but the activity of a major shareholder like Versant Venture Capital is always noteworthy.
• Comparable transactions would be insider sales in other publicly traded biotechnology companies, such as those by venture capital firms after an IPO or during lock-up expirations.

Stakeholder Impact

• The sale of shares by a major shareholder like Versant Venture Capital could create short-term selling pressure on the stock.
• The transactions may influence investor sentiment, depending on how the market interprets the reasons for the sales.

Key Dates